This site is intended for healthcare professionals
Search

Find disease awareness content and relevant supporting materials

Learning Zone 326 Events 31 News 17132 Drugs 62460 Trials 8138 Guidelines 837 Journals 3403
Filter results
Sort by:
Relevance
to
Clinical trials
Clinical trial
14/04/08

A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis

To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with ulcerative colitis...

  • 1 min read
  • Source: ClinicalTrialsRegister.eu
Clinical trials
Clinical trial
03/05/13

A Long-Term Registry of Humira ® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely...

  • 1 min read
  • Source: Clinicaltrials.gov
Latest drug news
Drug news
27/05/23

FDA approves Yuflyma biosimilar for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.- Celltrion USA

Celltrion USA announced that the FDA has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar.

  • 1 min read
Journals
Journal
08/02/19

Adalimumab Effectiveness Up to Six Years in Adalimumab-naive Patients with Crohn's Disease: Results of the PYRAMID Registry.

Background: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira ®), as used in routine clinical practice.

  • 1 min read
  • Source: Inflammatory Bowel Diseases
Clinical trials
Clinical trial
17/02/14

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered...

  • 1 min read
  • Source: Clinicaltrials.gov
Journals
Journal
06/01/18

Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry.

Objectives: The aim of this study was to evaluate the effectiveness and safety of adalimumab (ADA) in children with ulcerative colitis (UC) previously treated with infliximab (IFX).

  • 1 min read
  • Source: Journal of Pediatric Gastroenterology and Nutrition
Journals
Journal
30/08/17

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.

Background and aim: Secondary loss of response to adalimumab (ADA-LOR) commonly occurs in patients with Crohn's disease (CD) treated with adalimumab (ADA).

  • 1 min read
  • Source: Journal of Gastroenterology and Hepatology
Clinical trials
Clinical trial
12/05/11

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory ulcerative colitis.

  • 1 min read
  • Source: Clinicaltrials.gov
Journals
Journal
01/12/17

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.

Introduction: Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA.

  • 1 min read
  • Source: Rheumatology and Therapy
Clinical trials
Clinical trial
24/05/11

Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (ADJUVITE)

The primary objective is to demonstrate a higher response rate at 2 months in the adalimumab arm versus the placebo...

  • 1 min read
  • Source: Clinicaltrials.gov
See more